Clinical Trial Update: Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of neoadjuvant docetaxel plus cisplatin for resectable non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Providence Health & Services | Conditions: Non-small-Cell Lung Carcinoma | Phase 2 | Status: TERMINATED